Meeting Overview | We are pleased to invite you to the Expert Practice SM in Hematology meeting in Brussels, Belgium, on 9 April 2011.
During this case-based meeting, leaders in the field discuss with participants, in an interactive format, clinical issues encountered daily by practicing physicians.
This meeting is restricted to healthcare professionals based outside of the United States. You will be asked to provide your credentials to register.
For available travel grants, please contact: travelgrants@prIMEoncology.org |
Location | The Brussels Marriott Hotel
Rue Auguste Orts 3-7/ Grand Place
1000 Brussels, Belgium
|
Target Audience | This educational activity is designed for hematologists, oncologists, and other healthcare providers involved and/or interested in the management of patients with hematologic malignancies. This meeting is restricted to healthcare professionals based outside of the United States. |
Learning Objectives |
- Discuss methodologies to properly diagnose and manage patients with indolent mantle cell lymphoma
- Summarize treatment options and strategies for the management of myelodysplastic syndromes
- Evaluate the use of prognostic markers to guide the therapeutic decision-making process in patients with chronic lymphocytic leukemia
- Assess currently available and emerging treatment options for multiple myeloma, and describe the importance of bone health in patients with multiple myeloma
- Summarize treatment options for patients with newly diagnosed and resistant/refractory chronic myelogenous leukemia
|
Faculty | Chairman
Aristoteles Giagounidis, MD, PhD
St Johannes Hospital
Duisburg, Germany |
Faculty
| Michel Delforge, MD, PhD
University Hospital Leuven
Leuven, Belgium
|
|
Carlo Gambacorti-Passerini, MD
San Gerardo Hospital
University of Milano Bicocca
Monza, Italy
|
| Georg Hess, MD
Johannes Gutenberg University Mainz
Mainz, Germany
|
|
Evangelos Terpos, MD, PhD
University of Athens
Athens, Greece
|
|
 Agenda |
| Friday, 8 April |
| 20.00-22.00 |
|
Welcome reception and dinner |
| Saturday, 9 April |
| 9.00 |
|
Welcome, introduction and demographic questions
Aristoteles Giagounidis, MD, PhD |
| 9.20 |
|
Case #1—Low-risk myelodysplastic syndromes: Is there a new standard of care?
Aristoteles Giagounidis, MD, PhD |
| 9.55 |
|
Case #2—Mantle cell lymphoma- New options on the horizon
Georg Hess, MD
|
| 10.30 |
|
Break |
| 11.00 |
|
Case #3—Multiple myeloma (MM): Treatment of the non-transplant patient
Michel Delforge, MD, PhD
|
| 11.35 |
|
Case #4—Comprehensive approaches for a patient with newly-diagnosed MM: Bone-targeted therapy
Evangelos Terpos, MD, PhD |
| 12.10 |
|
Case #5—Relapsed/refractory MM: Advances in treatment
Michel Delforge, MD, PhD
|
| 12.45 |
|
Lunch |
| 13.45 |
|
Case #6—Evolving standards of care for newly diagnosed chronic myelogenous leukemia (CML)
Carlo Gambacorti-Passerini, MD |
| 14.20 |
|
Case #7—Second-line treatment of CML: Selecting the appropriate therapy
Carlo Gambacorti-Passerini, MD
|
| 14.55 |
|
Case#8—Relapsed non-Hodgkin lymphoma: Novel approaches for patient management
Georg Hess, MD
|
| 15.30 |
|
Concluding remarks |
|
|
|
|
Downloadable Slides | Case #1
Low-risk myelodysplastic syndromes: Is there a new standard of care?
Aristoteles Giagounidis, MD, PhD
Case #2
Mantle cell lymphoma- New options on the horizon
Georg Hess, MD
Case #3
Multiple myeloma (MM): Treatment of the non-transplant patient
Michel Delforge, MD, PhD
Case #4
Comprehensive approaches for a patient with newly-diagnosed MM: Bone-targeted therapy
Evangelos Terpos, MD, PhD
Case #5
Relapsed/refractory MM: Advances in treatment
Michel Delforge, MD, PhD
Case #6
Evolving standards of care for newly diagnosed chronic myelogenous leukemia (CML)
Carlo Gambacorti-Passerini, MD
Case #7
Second-line treatment of CML: Selecting the appropriate therapy
Carlo Gambacorti-Passerini, MD
Case#8
Relapsed non-Hodgkin lymphoma: Novel approaches for patient management
Georg Hess, MD |
Organizer | This meeting is a prIME Oncology activity.
|
Support | Support for this activity has been provided by Celgene, Novartis Oncology and Pfizer Oncology.
|
|
